US Pharm. 2009;34(11):5.
Silver Spring, MD — The FDA approved the vaccine Gardasil for the prevention of genital warts resulting from the human papillomavirus (HPV) types 6 and 11 in boys and men age 9 through 26 years. A randomized trial of 4,055 males age 16 through 26 showed that Gardasil was 90% effective in preventing genital warts, and studies measuring the immune response of males age 9 through 15 were equally positive. Each year, about two out of every 1,000 men in the United States are diagnosed with genital warts. Gardasil currently is approved for use in girls and women age 9 through 26 for the prevention of cervical, vulvar, and vaginal cancer caused by HPV types 16 and 18; precancerous lesions caused by types 6, 11, 16, and 18; and genital warts caused by types 6 and 11. Most genital warts are caused by HPV infection, which is the most common sexually transmitted infection in the U.S.